Transplant in myeloma: what is its role?
- 5 December 2025
- journal article
- review article
- Published by American Society of Hematology in Hematology-American Society Hematology Education Program
- Vol. 2025 (1) , 401-404
Abstract
Quadruplet induction regimens containing anti-CD38 monoclonal antibodies in combination with a triplet backbone are providing deeper and more durable responses in newly diagnosed multiple myeloma (NDMM) patients, and at the same time, questioning the role of autologous stem cell transplant as part of consolidation, especially in certain subgroups. While several studies are evaluating the rate of sustained minimal residual disease (MRD) achieved when combining quadruplet regimens to transplant, other studies are focusing on the relevance of pursuing transplant in those who achieved MRD with induction. Current evidence supports autologous stem cell transplant as a key consolidation strategy while ongoing studies refine risk-adapted and MRD-guided approaches. We have yet to see how new immunotherapies that are moving to front-line therapy will challenge the role of transplant in the future.Keywords
This publication has 15 references indexed in Scilit:
- Isatuximab, Lenalidomide, Bortezomib, and Dexamethasone Induction Therapy for Transplant-Eligible Newly Diagnosed Multiple Myeloma: Final Part 1 Analysis of the GMMG-HD7 TrialJournal of Clinical Oncology, 2025
- Daratumumab plus bortezomib, lenalidomide and dexamethasone for transplant-ineligible or transplant-deferred newly diagnosed multiple myeloma: the randomized phase 3 CEPHEUS trialNature Medicine, 2025
- Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple MyelomaNew England Journal of Medicine, 2024
- Results of the Phase III Randomized Iskia Trial: Isatuximab-Carfilzomib-Lenalidomide-Dexamethasone Vs Carfilzomib-Lenalidomide-Dexamethasone As Pre-Transplant Induction and Post-Transplant Consolidation in Newly Diagnosed Multiple Myeloma PatientsBlood, 2023
- Autologous stem cell transplantation in patients older than 65 years with multiple myeloma: a real-world studyHematology, Transfusion and Cell Therapy, 2023
- Triplet Therapy, Transplantation, and Maintenance until Progression in MyelomaNew England Journal of Medicine, 2022
- Early Versus Late Autologous Stem Cell Transplant in Newly Diagnosed Multiple Myeloma: Long-Term Follow-up Analysis of the IFM 2009 TrialBlood, 2020
- Autologous stem cell transplant in older patients (age ≥ 65) with newly diagnosed multiple myeloma: A systematic review and meta-analysisJournal of Geriatric Oncology, 2020
- Lenalidomide, Bortezomib, and Dexamethasone with Transplantation for MyelomaNew England Journal of Medicine, 2017
- Bortezomib with lenalidomide and dexamethasone versus lenalidomide and dexamethasone alone in patients with newly diagnosed myeloma without intent for immediate autologous stem-cell transplant (SWOG S0777): a randomised, open-label, phase 3 trialThe Lancet, 2017